An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

Rosiglitazone XR

Number of Participants With Any Adverse Events (AEs) and Severity of AEs

Number Participants With Serious Adverse Events (SAEs) and Deaths

Number of Participants With Adverse Event of Oedema

Change From Baseline in Vital Sign Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Change From Baseline in Vital Sign Heart Rate (HR)

Change From Baseline in Vital Sign Body Weight (BW)

Change From Baseline in Non-fasting Measures of Lipid Metabolism Namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides

Number of Participants With SBP and DBP Values of Potential Clinical Concern (PCC)

Number of Participants With HR Values of PCC ATOT

Number of Participants With BW Values of PCC ATOT

Number of Participants With Hematology Parameters of PCC ATOT

Number of Participants With Clinical Chemistry Parameters (Including Lipids) of PCC ATOT

Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score as a Function of Apolipoprotein E (APOE) ε4 Status.

Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score as a Function of APOE ε4 Status.

Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE ε4 Status.

Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOE ε4 Status.

Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE ε4 Status.